Correlative End Points
tumor
TUMOR, METASTATIC TUMOR
Preregistration metastatic tumor biopsy specimens were evaluated for AURKA expression (negative expression defined as 0%-10% of tumor cells with IHC staining present) and ERα expression (negative expression defined as <10% of tumor cells with IHC staining present). Cox modeling was used to explore whether PFS differed in either treatment arm regarding preregistration tumor AURKA expression or ERα expression.